A synthetic GHRH analog researched for prolonged GH and IGF-1 stimulation, including albumin-binding DAC versions.
Pre-loaded with a typical CJC-1295 vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for CJC-1295. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 2 mg – 4.5 mg | single dose or multi-dose weekly-style cohorts | subcutaneous | Teichman et al. healthy-adult study of CJC-1295 with DAC Published human doses were approximately 30-60 mcg/kg; absolute mcg depends on body weight. This refers to the DAC form. |
| 100 mcg – 300 mcg | one to three times daily | subcutaneous | Commonly cited research-protocol ranges for non-DAC / Mod GRF 1-29 style analogs Short-acting non-DAC sequences are discussed at much lower, more frequent amounts than DAC CJC-1295. |
People searching this page also look for: cjc 1295 peptide dosage, cjc-1295 peptide dosage, peptide cjc 1295 dosage, cjc-1295 peptide benefits side effects dosage.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered to extend stimulation of pituitary GH release relative to native GHRH(1-29). The best-known research form includes a Drug Affinity Complex (DAC) moiety that enables covalent albumin binding after injection, markedly prolonging half-life and supporting multi-day GH/IGF-1 elevations in published human pharmacokinetic studies.
Investigators value CJC-1295 as a tool compound for GH-axis pharmacology: it helped demonstrate that prolonged GHRH-receptor stimulation can raise GH and IGF-1 while still preserving pulsatile GH patterns in healthy adults. A shorter-acting related sequence (often discussed as CJC-1295 without DAC / Mod GRF 1-29) is used when labs want brief pulses instead of multi-day exposure.
Research-grade CJC-1295 is Research Use Only. It is not FDA-approved for human use and is not for human consumption. Reported ranges differ sharply between DAC and non-DAC forms; the figures below are literature references, not recommendations.
CJC-1295 acts at the GHRH receptor on anterior-pituitary somatotrophs. Receptor activation increases cAMP and triggers GH secretion. In the DAC-bearing form, reactive conjugation to circulating albumin slows clearance, producing sustained GHRH-receptor tone. Downstream, elevated GH drives hepatic and local IGF-1 production. Studies report that physiologic GH pulsatility can persist even under continuous analog stimulation.
GH/IGF-1 axis pharmacology · long-acting GHRH analog design · pituitary somatotroph signaling · body-composition biomarker research · albumin-bioconjugate peptide PK
Endocrine pharmacologists, peptide-engineering groups, and GH-axis biology labs are the main audience. Anti-doping analytics groups have also published detection methods because GHRH analogs appear on prohibited-substance lists in sport contexts.
Store lyophilized peptide refrigerated or frozen, away from light and humidity. After reconstitution, refrigerate and aliquot if the protocol requires repeated sampling over multiple days.
Research protocols frequently examine CJC-1295 together with a ghrelin-mimetic GHRP or GHS-R agonist such as ipamorelin or hexarelin because GHRH and ghrelin pathways can converge on GH release through complementary receptors. DAC versus non-DAC choice is usually the first experimental branch point.
The questions people actually search for, answered plainly.
For CJC-1295 with DAC, Teichman et al. studied about 30-60 mcg/kg subcutaneously in healthy adults. Non-DAC analogs are commonly discussed around 100-300 mcg per exposure because they clear much faster.
DAC enables albumin binding and multi-day activity. Without DAC, the peptide behaves like a short-acting GHRH analog and is typically studied with more frequent administration.
Published work reported that pulsatile GH secretion can persist during continuous stimulation by long-acting CJC-1295, with higher mean and trough GH levels.
No. Research-grade CJC-1295 is RUO laboratory material and is not an approved drug product for human use.
GHRH-receptor and ghrelin-receptor pathways both influence GH release. Combination designs are used to study synergy and dual-input control of somatotroph output.
Human PK work reported a half-life on the order of roughly one week, with IGF-1 elevations lasting days after dosing in study cohorts.
Lyophilized 2 mg and 5 mg vials are common research presentations, reconstituted to a working concentration chosen for the assay or protocol.
Primary literature on CJC-1295. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides